On Tuesday, Protagonist Therapeutics Inc (NASDAQ: PTGX) was 2.77% up from the session before settling in for the closing price of $44.39. A 52-week range for PTGX has been $24.78 – $60.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 2607.12%. When this article was written, the company’s average yearly earnings per share was at -130.94%. With a float of $57.88 million, this company’s outstanding shares have now reached $61.04 million.
Considering the fact that the conglomerate employs 126 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 99.61%, operating margin of 58.2%, and the pretax margin is 64.32%.
Protagonist Therapeutics Inc (PTGX) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Protagonist Therapeutics Inc stocks. The insider ownership of Protagonist Therapeutics Inc is 5.71%, while institutional ownership is 100.01%. The most recent insider transaction that took place on Apr 22 ’25, was worth 80,776. In this transaction Chief Financial Officer of this company sold 1,756 shares at a rate of $46.00, taking the stock ownership to the 61,065 shares. Before that another transaction happened on Mar 17 ’25, when Company’s Director sold 4,000 for $54.25, making the entire transaction worth $217,000. This insider now owns 13,130 shares in total.
Protagonist Therapeutics Inc (PTGX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.53 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -130.94% per share during the next fiscal year.
Protagonist Therapeutics Inc (NASDAQ: PTGX) Trading Performance Indicators
You can see what Protagonist Therapeutics Inc (PTGX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 12.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.45. Likewise, its price to free cash flow for the trailing twelve months is 15.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 4.21, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -1.01 in one year’s time.
Technical Analysis of Protagonist Therapeutics Inc (PTGX)
Compared to the last year’s volume of 1.06 million, its volume of 0.95 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 34.66%. Additionally, its Average True Range was 2.26.
During the past 100 days, Protagonist Therapeutics Inc’s (PTGX) raw stochastic average was set at 44.31%, which indicates a significant decrease from 69.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.29% in the past 14 days, which was lower than the 73.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $45.53, while its 200-day Moving Average is $42.55. Nevertheless, the first resistance level for the watch stands at $46.52 in the near term. At $47.41, the stock is likely to face the second major resistance level. The third major resistance level sits at $48.83. If the price goes on to break the first support level at $44.21, it is likely to go to the next support level at $42.79. Now, if the price goes above the second support level, the third support stands at $41.90.
Protagonist Therapeutics Inc (NASDAQ: PTGX) Key Stats
There are 61,384K outstanding shares of the company, which has a market capitalization of 2.80 billion. As of now, sales total 434,430 K while income totals 275,190 K. Its latest quarter income was 170,640 K while its last quarter net income were 131,670 K.
